Mechanistic insight for drug development
Supporting R&D decisions in complex or high-risk programs.
SPILLO supports pharma and biotech teams in understanding drug efficacy and safety through unbiased, physics-based identification of targets and off-targets across the structural proteome.
Independent Experimental Validation reported in peer-reviewed studies
Scientific Report (2021) - “Tubulin binding potentially clears up Bortezomib and Carfilzomib differential neurotoxic effect” - DOI: 10.1038/s41598-021-89856-3
Bioorganic & Medicinal Chemistry (2020) - “3D proteome-wide scale screening and activity evaluation of a new ALKBH5 inhibitor in U87 glioblastoma cell line” - DOI: 10.1016/j.bmc.2019.115300
Biology (2022) - “MV1035 Overcomes Temozolomide Resistance in Patient-Derived Glioblastoma Stem Cell Lines” - DOI: 10.3390/biology11010070
Frontiers in Pharmacology (2024) - “Fraisinib: a calixpyrrole derivative reducing A549 cells-derived NSCLC tumor in-vivo, acts as ligand of the Glycine-tRNA Synthase, a new molecular target in oncology” - DOI: 10.3389/fphar.2023.1258108
Journal of Medicinal Chemistry (2021) - “Three-dimensional proteome-wide scale screening for the 5-alpha reductase inhibitor Finasteride: identification of a novel off-target” - DOI: 10.1021/acs.jmedchem.0c02039
Journal of Molecular Structure (2022) - “Identification of a novel off-target of paroxetine: Possible role in sexual dysfunction induced by this SSRI antidepressant drug” - DOI: 10.1016/j.molstruc.2022.133690
Website coming soon.
For inquiries: info@spillo.ch
_____________
_____________
_____________